https://www.selleckchem.com/pr....oducts/ly-3475070.ht
compared with (226 of 12 927 assigned to vitamin D [1.7%] and 274 of 12 944 assigned to placebo [2.1%]; HR, 0.83 [95% CI, 0.69-0.99]; P = .04). When stratified by BMI, there was a significant reduction for the vitamin D arm in incident metastatic or fatal cancer among those with normal BMI (BMI25 HR, 0.62 [95% CI, 0.45-0.86]) but not among those with overweight or obesity (BMI 25-30 HR, 0.89 [95% CI, 0.68-1.17]; BMI≥30 HR, 1.05 [95% CI, 0.74-1.49]) (P = .03 for interaction by BMI). In this randomized clinical trial, supplemen
Like
Comment
Share
